Published in Vaccine on July 27, 2011
Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies. Cells (2012) 1.12
Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol (2012) 0.97
The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Vaccine (2014) 0.84
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56
Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med (1997) 7.59
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA (2006) 7.46
Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med (2002) 6.23
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods (2007) 4.69
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods (2002) 4.48
Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA (2008) 4.19
Genital herpes. Lancet (2007) 3.83
Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods (2007) 3.29
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis (1992) 3.27
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet (1993) 2.71
Neonatal herpes simplex infection. Clin Microbiol Rev (2004) 2.06
Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods (2006) 1.76
Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis (1994) 1.73
Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J Virol (1992) 1.71
Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol (2006) 1.43
Socioeconomic and race/ethnic patterns in persistent infection burden among U.S. adults. J Gerontol A Biol Sci Med Sci (2009) 1.41
High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J Virol (1996) 1.40
Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect Dis (2005) 1.34
T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity? J Immunol (2003) 1.29
Inaccuracy of certain commercial enzyme immunoassays in diagnosing genital infections with herpes simplex virus types 1 or 2. Am J Clin Pathol (2003) 1.12
Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol (2008) 1.12
Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol (2010) 1.10
Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. Sex Transm Dis (2004) 1.06
Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects. Clin Vaccine Immunol (2008) 0.93
Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpes. Virol J (2006) 0.92
Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J Immunol (2008) 0.88
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2002) 6.99
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med (2009) 5.47
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis (2007) 4.52
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA (2003) 4.38
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA (2008) 4.19
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis (2008) 4.05
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis (2007) 3.95
Genital herpes. Lancet (2007) 3.83
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Frequent and prolonged shedding of bocavirus in young children attending daycare. J Infect Dis (2010) 3.67
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med (2007) 3.66
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol (2004) 3.56
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J Clin Microbiol (2006) 3.37
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis (2004) 3.23
Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis (2004) 3.23
Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis (2003) 3.19
A population-based study of primary human herpesvirus 6 infection. N Engl J Med (2005) 3.07
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis (2004) 3.01
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 2.97
Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol (2005) 2.89
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine (2006) 2.89
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
Maternal and neonatal herpes simplex virus infections. N Engl J Med (2009) 2.85
Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol (2002) 2.83
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis (2008) 2.77
Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med (2012) 2.77
Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol (2002) 2.71
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis (2002) 2.67
Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol (2003) 2.64
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis (2011) 2.56
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet (2012) 2.54
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood (2002) 2.48
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer (2012) 2.48
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis (2010) 2.45
Genital herpes complicating pregnancy. Obstet Gynecol (2005) 2.45
Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis (2006) 2.43
Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol (2007) 2.42
Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood (2003) 2.41
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood (2003) 2.40
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature (2013) 2.38
Electronic origin of high-temperature superconductivity in single-layer FeSe superconductor. Nat Commun (2012) 2.37
Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer (2010) 2.37
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med (2014) 2.36
Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS (2007) 2.35
The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med (2005) 2.34
Phase diagram and electronic indication of high-temperature superconductivity at 65 K in single-layer FeSe films. Nat Mater (2013) 2.34
Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis (2007) 2.33